Monopar Therapeutics Inc (MNPR) Stock AnalysisMNPRMonopar Therapeutics Inc

Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company developing treatments for Wilson disease and novel radiopharmaceuticals for oncology. The Company’s product candidates are ALXN1840, MNPR-101, MNPR-101-Zr, MNPR-101-Lu, and MNPR-101-Ac. The Company’s Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. Its radiopharmaceutical program consists of MNPR-101, a proprietary humanized monoclonal antibody that is being developed across multiple product candidates conjugated with different radioisotopes, for the treatment of advanced solid tumors. MNPR-101-Zr is the Company’s clinical-stage radiodiagnostic imaging agent comprised of MNPR-101 conjugated to zirconium-89. MNPR-101-Lu is its clinical-stage radiotherapeutic comprised of MNPR-101 conjugated to lutetium-177. MNPR-101-Ac is late-preclinical stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Monopar Therapeutics Inc is a good buy right now due to its recent stock price of $111.89, which is significantly lower than the analyst price target of $133 from BTIG. The company has shown a remarkable year-to-date change of +69.50% and a one-year change of +229.77%, indicating strong momentum. However, the main risk is the negative net income reported for Q2 2026, which was -5,313,300 USD, suggesting ongoing financial challenges that investors should monitor closely.